

News Release

Irvine, CA --- October 23, 2015



ImmunogenX™

ImmunogenX has closed a Class B oversubscribed investment round

The funds will enable the next phase clinical trial

ImmunogenX™ has completed its second investment round (Class B) in record time and raised 20% more than its target. These funds will be used to initiate an expanded clinical trial for the CypCel™ diagnostic tool for measuring the intestinal health of celiac disease patients under treatment. A highly successful preliminary clinical trial proved the feasibility of the method (Moron et. al., Am J Gastroenterol 2013; 108: 1-8). The next phase study will be conducted at the Mayo Clinic under the co-Principal Investigatorship of Dr. Joseph Murray.

Dr. Jack A. Syage, CEO of ImmunogenX remarked “We are ecstatic by the investor enthusiasm for this round and the prospects of our diagnostic disease management tool CypCel. Celiac disease is a huge problem afflicting about 1% of the world's population and we are filling an unmet need for a means to monitor intestinal health in celiac patients under treatment.”

The Mayo Clinic will conduct a first phase trial which will then be followed by an expanded trial led by the Mayo Clinic and to also include Columbia University, University of Chicago, and Beth Israel Hospital (Harvard), all world's leading celiac disease centers.

About ImmunogenX

“ImmunogenX” (a subsidiary of Immunogenics LLC) is a clinical-stage company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. ImmunogenX is developing new advanced diagnostic screening methods to help individuals diagnosed with celiac disease. For disease management we are extending and commercializing a successful clinical study for a metabolic marker compound that can measure the state of recovery of a celiac patient undergoing gluten-free diet treatment. This is a unique capability for which there are no other effective diagnostics. For food safety we are pioneering advanced methods to identify new physiologically relevant gluten peptide sequences in wheat, barley, and rye grain to greatly improve on the capability to screen for the full range of gluten proteins in food products.

www.Immunogenx.com

For further information please contact

Jack A. Syage, PhD, CEO
714 357-0631
jsyage@immunogenx.com

“ImmunogenX™”, “Immunogenics™”, “CypCel™”, and “Allergenomics™” are trademarks of Immunogenics LLC